Compare Pfizer Inc (PFE) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Pfizer Inc trades at $27.83 (market cap $158.56B), while VanEck Rare Earth/Strategic Metals trades at $61.8 (market cap $1.75B). The key difference: Pfizer Inc is far larger — about 90.6× VanEck Rare Earth/Strategic Metals's market cap, and Pfizer Inc pays a 6.18% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| PFE | REMX | |
|---|---|---|
Market Cap | $158.56B | $1.75B |
Volume | 44,138,282 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $29.02 | $109.53 |
52-Week Low | $23.67 | $60.58 |
Typical Hold Time | 158 Days | 50 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
REMX (VanEck Rare Earth and Strategic Metals ETF) is trading at $61.88, down 2.99% with a bearish technical signal. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 23 suggest potential oversold conditions. Recent news highlights increased institutional interest from Bank of America while the rare earth sector navigates geopolitical tensions and U.S. supply chain developments.
The ETF's high volatility (~50% annualized) and China-heavy exposure present significant risks, though strategic importance of rare earth metals for defense and technology offers long-term thematic appeal. Current technical weakness contrasts with fundamental tailwinds from U.S. supply chain initiatives, creating a contested investment case requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
